Mirati Therapeutics

Loading quotes...

Forecast

The analysts' average price target is €92.62 (+73.77%). The median is €60.33 (+13.19%).

Buy	14
Hold	17
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Mirati Therapeutics had revenue of €11.59m and net profit of -€690.67m

(EUR)	2022	YoY
Revenue	11.59m	81.71%
Gross profit	11.03m	102.87%
Net profit	-690.67m	35.00%
EBITDA	-705.4m	40.38%

Fundamentals

Metric	Value
Market capitalization	€3.74bn
Number of shares	70.15m
52-week high/low	€58.43 - €24.77
Dividends	No
Beta	0.77
P/E ratio	-4.45
PEG ratio	-0.39
P/B ratio	3.31
P/S ratio	331.11

Company profile

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.